The expression of the virulence-associated genes ureA, encoding the urease subunit A, and nap, encoding the neutrophil activating protein, in Helicobacter pylori grown both in the stomach of C57/Bl6 mice and in Brucella broth was quantified by quantitative competitive reverse transcriptase-PCR using a homologous RNA standard (competitor) and an external standard (16S rRNA). The results showed that the ureA and nap transcripts were increased up to 15 and 80 times, respectively, in vivo compared to in vitro. The transcription of ureA and nap also differed in that ureA showed highest expression early in infection in mice whereas nap transcription was variable throughout the 18-week infection period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1574-695X.2002.tb00557.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thermally Bisignate Anion Responsive Supramolecular Gel and Generation of a Conductive Hybrid-Gel Nanocomposite.
Langmuir
November 2024
Department of Chemistry, Indian Institute of Technology Guwahati, Assam 781039, India.
Understanding the structure-function relationship is a significant challenge in designing supramolecular soft materials such as supramolecular gels. To address this challenge, we report on two urea-based dipodal ligands, and , with different terminal substituents influencing their gelation properties. The terminal substituents play a crucial role in the gelation abilities.
View Article and Find Full Text PDFCost-effectiveness of adding quizartinib to induction chemotherapy for patients with mutant acute myeloid leukemia.
Leuk Lymphoma
August 2024
Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Article Synopsis
- Quizartinib, an FLT3 inhibitor, boosts overall survival for newly diagnosed AML patients aged 18-75 with an ITD mutation when combined with intensive chemotherapy ("7 + 3").
- A cost-effectiveness analysis revealed that adding quizartinib to standard treatment incurs additional costs of $289,932, yielding only 0.84 more quality-adjusted life years (QALYs).
- The incremental cost-effectiveness ratio stands at $344,039/QALY, suggesting quizartinib would only be considered cost-effective with substantial price reductions or specific treatment adjustments.
Identification, Genome Sequencing, and Characterizations of Sourced from Pakistan.
Microorganisms
October 2023
Department of Microbiology, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad 45320, Pakistan.
The stomach's colonization by () results in gastritis, ulcers, and stomach cancer. Frequently, pain is treated with medication, but resistant infections are not. Therefore, it is important to find pharmacological targets and improved treatments for resistant strains.
View Article and Find Full Text PDFProtective immunity enhanced vaccine vectors delivering antigens reduce stomach colonization in mice.
Front Immunol
December 2022
Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, Florida, FL, United States.
is a major cause of gastric mucosal inflammation, peptic ulcers, and gastric cancer. Emerging antimicrobial-resistant has hampered the effective eradication of frequent chronic infections. Moreover, a safe vaccine is highly demanded due to the absence of effective vaccines against .
View Article and Find Full Text PDFSecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Blood Adv
March 2023
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT.
Article Synopsis
- Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and essential thrombocythemia (ET) have a higher risk of developing second malignancies (SMs).
- A study investigated the relationship between hydroxyurea (HU) therapy and the occurrence of SMs in older patients (age ≥66) with MPNs, using a Medicare-linked database and a cohort of 4023 patients.
- The findings indicated that there was no significant difference in the risk of SMs, including severe conditions like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), between patients who used HU and those who did not
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!